Page 163 - 2018_12-Haematologica-web

Subgroup analyses of CASTOR
6. Jakubowiak A, Offidani M, Pegourie B, et al. Randomized phase 2 study of elotuzumab plus bortezomib/dexamethasone (Bd) ver- sus Bd for relapsed/refractory multiple myeloma. Blood. 2016;127(33):2833-2840.
7. de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematologi- cal tumors. J Immunol. 2011;186(3):1840- 1848.
8. Lammerts van Bueren J, Jakobs D, Kaldenhoven N, et al. Direct in vitro com- parison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79. Blood. 2014;124 (21):3474.
9. Overdijk MB, Verploegen S, Bogels M, et al. Antibody-mediated phagocytosis con- tributes to the anti-tumor activity of the therapeutic antibody daratumumab in lym- phoma and multiple myeloma. MAbs. 2015;7(2):311-321.
10. Overdijk MB, Jansen JH, Nederend M, et al. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcgamma receptor-mediated cross- linking. J Immunol. 2016;197(3):807-813.
11. van de Donk NWCJ, Janmaat ML, Mutis T, et al. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol Rev. 2016;270(1):95-112.
12. Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38+ immune- regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384-394.
13. Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexam- ethasone for multiple myeloma. N Engl J Med. 2016;375(8):754-766.
14. Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexam- ethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319-1331.
15. DARZALEX® (daratumumab) injection, for intravenous use [package insert]. Horsham, PA: Janssen Biotech, Inc.; 2018.
16. European Medicines Agency. DARZALEX summary of product characteristics, May 2016. Available at: http:// www.ema.europa.eu/docs/en_GB/docu- ment_library/EPAR_-_Product_ Information/human/004077/WC500207296 .pdf. Last accessed July 2018.
17. Durie BGM, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9): 1467-1473.
18. Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uni- form reporting of clinical trials: report of the
International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18): 4691-4695.
19. Chiu C, Soong D, Spicka I, et al. Next gener- ation sequencing (NGS) methodology for determining cytogenetic risk status in the daratumumab phase 3 CASTOR and POL- LUX studies in relapsed or refractory multi- ple myeloma (RRMM). Presented at: the 22nd Congress of the European Hematology Association (EHA); June 22-25, 2017; Madrid, Spain. Abstract S100.
20. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group con- sensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328- e346.
21. Martinez-Lopez J, Lahuerta JJ, Pepin F, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014;123(20):3073-3079.
22. Rawstron AC, Gregory WM, de Tute RM, et al. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. Blood. 2015;125(12):1932-1935.
30. Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexametha- sone for multiple myeloma. N Engl J Med. 2016;374(17):1621-1634.
31. Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014;123(12):1826- 1832.
32. San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexametha- sone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a ran- domised, open-label, phase 3 trial. Lancet Oncol. 2013;14(11):1055-1066.
33. Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207-1219.
34. Lonial S, Weiss BM, Usmani S, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016; 387(10027):1551-1560.
35. Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dex- amethasone in relapsed and/or refractory multiple myeloma. Blood. 2017; 130(8):974-
23. McCarthy PL, Palumbo A. Maintenance
therapy for multiple myeloma. Hematol
Oncol Clin North Am. 2014;28(5):839-859. 981.
24. Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dex- amethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371 (10):906-917.
25. Dimopoulos MA, Weisel KC, Song KW, et al. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexametha- sone. Haematologica. 2015;100(10):1327- 1333.
26. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multi- ple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood. 2007;109(8):3489-3495.
27. Avet-Loiseau H, Hulin C, Campion L, et al. Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe fran- cophone du myelome experience. J Clin Oncol. 2013;31(22):2806-2809.
28. Chng WJ, Dispenzieri A, Chim CS, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28(2): 269-277.
29. Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexam- ethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142-152.
36. Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refracto- ry multiple myeloma. N Engl J Med. 2015;373(7):621-631.
37. Dimopoulos MA, Goldschmidt H, Niesvizky R, et al. Carfilzomib or borte- zomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, ran- domised, phase 3 trial. Lancet Oncol. 2017;18:1327-1337.
38. Boudreault JS, Touzeau C, Moreau P. Triplet combinations in relapsed/refractory myelo- ma: update on recent phase 3 trials. Expert Rev Hematol. 2017;10(3):207-215.
39. Yee AJ, Raje NS. Sequencing of nontrans- plant treatments in multiple myeloma patients with active disease. Hematology Am Soc Hematol Educ Program. 2016;2016 (1):495-503.
40. van Beurden-Tan CH, Franken MG, Blommestein HM, Uyl-de Groot CA, Sonneveld P. Systematic literature review and network meta-analysis of treatment outcomes in relapsed and/or refractory mul- tiple myeloma. J Clin Oncol. 2017;35:1313- 1319.
41. Areethamsirikul N, Reece DE. The risk of secondary primary malignancies after thera- py for multiple myeloma. Leuk Lymphoma. 2015;56(11):3012-3021.
haematologica | 2018; 103(12)
2087